SG10201800982QA - Humanized or chimeric cd3 antibodies - Google Patents

Humanized or chimeric cd3 antibodies

Info

Publication number
SG10201800982QA
SG10201800982QA SG10201800982QA SG10201800982QA SG10201800982QA SG 10201800982Q A SG10201800982Q A SG 10201800982QA SG 10201800982Q A SG10201800982Q A SG 10201800982QA SG 10201800982Q A SG10201800982Q A SG 10201800982QA SG 10201800982Q A SG10201800982Q A SG 10201800982QA
Authority
SG
Singapore
Prior art keywords
humanized
chimeric
antibodies
Prior art date
Application number
SG10201800982QA
Other languages
English (en)
Inventor
Den Brink Edward Van
Joost J Neijssen
Aran Frank Labrijn
Joyce Meesters
Janine Schuurman
Paul Parren
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2013/064330 external-priority patent/WO2014006217A1/en
Application filed by Genmab As filed Critical Genmab As
Publication of SG10201800982QA publication Critical patent/SG10201800982QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10201800982QA 2013-07-05 2014-07-04 Humanized or chimeric cd3 antibodies SG10201800982QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2013/064330 WO2014006217A1 (en) 2012-07-06 2013-07-05 Dimeric protein with triple mutations
DKPA201400009 2014-01-09
PCT/EP2014/050340 WO2014108483A1 (en) 2013-01-10 2014-01-09 Inert format

Publications (1)

Publication Number Publication Date
SG10201800982QA true SG10201800982QA (en) 2018-03-28

Family

ID=52143134

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201800982QA SG10201800982QA (en) 2013-07-05 2014-07-04 Humanized or chimeric cd3 antibodies
SG11201510739TA SG11201510739TA (en) 2013-07-05 2014-07-04 Humanized or chimeric cd3 antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201510739TA SG11201510739TA (en) 2013-07-05 2014-07-04 Humanized or chimeric cd3 antibodies

Country Status (31)

Country Link
US (5) US10465006B2 (pl)
EP (5) EP3693385A1 (pl)
JP (7) JP6546162B2 (pl)
KR (4) KR102813816B1 (pl)
CN (5) CN105722529B (pl)
AU (4) AU2014286116A1 (pl)
BR (1) BR122023002590B1 (pl)
CA (1) CA2915575A1 (pl)
CY (1) CY1122840T1 (pl)
DK (2) DK3016681T5 (pl)
EA (1) EA201690167A1 (pl)
ES (2) ES2776706T3 (pl)
FI (2) FI4249515T3 (pl)
HK (1) HK1231369A1 (pl)
HR (2) HRP20200382T1 (pl)
HU (2) HUE048722T2 (pl)
IL (4) IL311371B2 (pl)
LT (2) LT3016681T (pl)
ME (1) ME03675B (pl)
MX (2) MX373245B (pl)
NL (1) NL301352I2 (pl)
NZ (1) NZ715896A (pl)
PL (1) PL3016681T3 (pl)
PT (2) PT3016681T (pl)
RS (2) RS60131B1 (pl)
SG (2) SG10201800982QA (pl)
SI (2) SI3016681T1 (pl)
SM (2) SMT202000287T1 (pl)
UA (1) UA119646C2 (pl)
WO (2) WO2015001085A1 (pl)
ZA (1) ZA201800385B (pl)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX349057B (es) 2010-11-30 2017-07-07 Chugai Pharmaceutical Co Ltd Agente terapeutico que induce citotoxicidad.
WO2014006217A1 (en) 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
MX373245B (es) 2013-07-05 2020-05-11 Genmab As Anticuerpos cd3 humanizados o quiméricos.
RU2727836C2 (ru) 2013-07-25 2020-07-24 Сайтомкс Терапьютикс, Инк. Мультспецифические антитела, мультспецифические активируемые антитела и способы их применения
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
CA2943943C (en) * 2014-04-07 2023-01-10 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
JP6894702B2 (ja) 2014-05-13 2021-06-30 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子
BR112017001579A2 (pt) 2014-07-25 2017-11-21 Cytomx Therapeutics Inc anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
SMT202000438T1 (it) 2014-11-17 2020-09-10 Regeneron Pharma Metodi per trattamento di tumore usando l'anticorpo bispecifico cd3xcd20
MX2017006571A (es) 2014-11-20 2017-09-29 Hoffmann La Roche Moleculas de union a antigeno biespecificas activadoras de celulas t.
PL3221357T3 (pl) 2014-11-20 2020-11-02 F. Hoffmann-La Roche Ag Wspólne łańcuchy lekkie i sposoby zastosowania
CN114478792A (zh) 2015-01-08 2022-05-13 根马布股份公司 针对cd3和cd20的双特异性抗体
PL3277725T3 (pl) 2015-03-30 2021-06-14 Regeneron Pharmaceuticals, Inc. Regiony stałe łańcucha ciężkiego o zmniejszonym wiązaniu do receptorów Fc gamma
UA128057C2 (uk) * 2015-07-15 2024-03-27 Ґенмаб А/С Гуманізоване або химерне антитіло, яке зв'язує cd3 людини
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
JP6931329B2 (ja) 2015-11-18 2021-09-01 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
US11649293B2 (en) 2015-11-18 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
CN105296421B (zh) * 2015-11-24 2019-01-29 高岱清 一种双特异性抗体活化的t细胞及制备方法与应用
EP4026848A1 (en) 2015-12-09 2022-07-13 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing the cytokine release syndrome
CN115850521A (zh) 2016-02-05 2023-03-28 奥里尼斯生物科学私人有限公司 靶向性治疗剂及其用途
MX2018011542A (es) * 2016-03-22 2019-02-07 Hoffmann La Roche Moleculas biespecificas de celulas t activadas por proteasas.
CN108884170A (zh) * 2016-03-22 2018-11-23 豪夫迈·罗氏有限公司 蛋白酶活化的t细胞双特异性分子
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
TW201902512A (zh) 2016-06-02 2019-01-16 瑞士商赫孚孟拉羅股份公司 治療方法
CA3026474A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
WO2018011421A1 (en) * 2016-07-14 2018-01-18 Genmab A/S Multispecific antibodies against cd40 and cd137
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
PT3592769T (pt) 2017-03-09 2024-07-31 Genmab As Anticorpos contra pd-l1
EP4108183A1 (en) 2017-03-30 2022-12-28 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
IL322042A (en) * 2017-05-08 2025-09-01 Adimab Llc Anti-CD3 binding sites and antibodies containing them, and methods of making and using them
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
EP3642229A1 (en) * 2017-06-21 2020-04-29 Gilead Sciences, Inc. Multispecific antibodies that target hiv gp120 and cd3
WO2019034580A1 (en) 2017-08-14 2019-02-21 Morphosys Ag HUMANIZED ANTIBODIES FOR CD3
US20190100587A1 (en) * 2017-10-02 2019-04-04 Covagen Ag IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
BR112020007309A2 (pt) 2017-10-14 2020-09-29 Cytomx Therapeutics, Inc. anticorpos, anticorpos ativáveis, anticorpos biespecíficos e anticorpos ativáveis biespecíficos e métodos de uso dos mesmos
KR101973060B1 (ko) 2017-10-20 2019-04-26 주식회사 녹십자 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물
CN107860925B (zh) * 2017-11-03 2019-07-12 合肥瀚科迈博生物技术有限公司 用于检测血清中HuA21抗体的ELISA检测试剂盒
CN109971725B (zh) 2017-12-28 2024-02-02 上海细胞治疗研究院 抗体修饰的嵌合抗原受体修饰t细胞及其用途
CN111787949A (zh) * 2018-02-15 2020-10-16 宏观基因有限公司 变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途
KR20200130723A (ko) 2018-03-12 2020-11-19 젠맵 에이/에스 항체
AU2019235523B2 (en) * 2018-03-14 2025-12-18 Novimmune Sa Anti-CD3 epsilon antibodies and methods of use thereof
BR112020022897A2 (pt) * 2018-05-23 2021-02-23 Pfizer Inc. anticorpos específicos para cd3 e usos dos mesmos
JP7530299B2 (ja) * 2018-05-24 2024-08-07 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３抗体及びその使用
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
LT3844189T (lt) 2018-08-31 2025-02-25 Regeneron Pharmaceuticals, Inc. Cd3/cd20 bispecifinių antikūnų dozavimo strategija, mažinanti citokinų išsiskyrimo sindromą
US20230124851A1 (en) 2018-10-11 2023-04-20 Inhibrx, lnc. B7h3 single domain antibodies and therapeutic compositions thereof
CN120623346A (zh) 2018-10-11 2025-09-12 因荷布瑞克斯生物科学公司 Pd-1单结构域抗体及其治疗组合物
US20210340273A1 (en) 2018-10-11 2021-11-04 Inhlbrx, inc. 5t4 single domain antibodies and therapeutic compositions thereof
CN113166263A (zh) 2018-10-11 2021-07-23 印希比股份有限公司 Dll3单域抗体及其治疗性组合物
WO2020106704A2 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2020052692A2 (en) * 2018-12-04 2020-03-19 Novartis Ag Binding molecules against cd3 and uses thereof
CU20210096A7 (es) 2019-05-21 2022-06-06 Novartis Ag Moléculas de unión a cd19
WO2021048423A1 (en) 2019-09-12 2021-03-18 Genmab A/S Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer
TWI841790B (zh) * 2019-09-30 2024-05-11 大陸商和鉑醫藥（上海）有限責任公司 靶向cd3的抗體、雙特異性抗體及其用途
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
CN114981297A (zh) 2019-12-23 2022-08-30 戴纳立制药公司 颗粒蛋白前体变体
US20230057263A1 (en) * 2020-01-06 2023-02-23 Cytomx Therapeutics, Inc. Single-and multi-chain polypeptides that bind specifically to cd3 epsilon
IL294879A (en) 2020-01-29 2022-09-01 Inhibrx Inc Monodomain antibodies of cd28 and their multivalent and multispecific constructs
US20230075244A1 (en) * 2020-02-20 2023-03-09 The Feinstein Institutes For Medical Research Agonist antibodies against endoglin and uses thereof
MY210125A (en) 2020-03-18 2025-08-28 Genmab As Antibodies binding to b7h4
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
JP2023524149A (ja) 2020-05-08 2023-06-08 ジェンマブ エー／エス Ｃｄ３およびｃｄ２０に対する二重特異性抗体
KR20230017841A (ko) 2020-05-27 2023-02-06 얀센 바이오테크 인코포레이티드 Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도
MX2023002194A (es) 2020-08-25 2023-03-03 Gilead Sciences Inc Moleculas multiespecificas de union a antigenos dirigidas al vih y metodos de uso.
JP2023539525A (ja) 2020-09-02 2023-09-14 ジェンマブ エー／エス 抗体療法
US20230355753A1 (en) 2020-09-10 2023-11-09 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
BR112023004327A2 (pt) 2020-09-10 2023-04-04 Genmab As Método para tratar leucemia linfocítica crônica em um sujeito humano
CA3192256A1 (en) 2020-09-10 2022-03-17 Brian Elliott Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
BR112023004351A2 (pt) 2020-09-10 2023-04-04 Genmab As Método para tratar linfoma folicular em um sujeito humano
CA3189883A1 (en) 2020-09-10 2022-03-17 Brian Elliott Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
MX2023002545A (es) 2020-09-10 2023-03-14 Genmab As Anticuerpo biespecifico contra cumulo de diferenciacion 3 (cd3) y cumulo de diferenciacion 20 (cd20) en terapia de combinacion para el tratamiento de linfoma difuso de celulas b grandes.
AU2021351187A1 (en) 2020-10-02 2023-04-20 Genmab A/S Antibodies capable of binding to ROR2 and bispecific antibodies binding to ROR2 and CD3
KR102671734B1 (ko) * 2021-04-13 2024-06-04 건국대학교 글로컬산학협력단 개과 동물의 CD3ε 특이적 항체 또는 그의 항원 결합 단편
JP7707306B2 (ja) 2021-04-30 2025-07-14 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による治療のための投薬
CA3213632A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
US20240383982A1 (en) 2021-05-07 2024-11-21 Genmab A/S Pharmaceutical compositions comprising bispecific antibodies binding to b7h4 and cd3
CN115558023A (zh) * 2021-07-02 2023-01-03 安源医药科技（上海）有限公司 抗cd3抗体及其用途
AU2022361691A1 (en) 2021-10-08 2024-03-28 Genmab A/S Antibodies binding to cd30 and cd3
KR20240144239A (ko) 2022-01-28 2024-10-02 젠맵 에이/에스 미만성 대 b-세포 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체
AU2023214116A1 (en) 2022-01-28 2024-07-18 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
IL314211A (en) 2022-03-23 2024-09-01 Genentech Inc Combined treatment of bispecific antibody and chemotherapy against CD20/ANTI-CD3
US20250304689A1 (en) 2022-04-13 2025-10-02 Genmab A/S Bispecific antibodies against cd3 and cd20
CA3255366A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Pharmaceutical compositions based on bispecific anti-CD20/anti-CD3 antibodies and methods of use
US20250304690A1 (en) * 2022-05-09 2025-10-02 Hangzhou Viromab Biotech Co., Ltd. Therapeutic agent comprising multispecific antibody and use thereof in tumor therapy
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
EP4612179A1 (en) 2022-11-02 2025-09-10 Genmab A/S Bispecific antibodies against cd3 and cd20 for treating richter's syndrome
WO2024102948A1 (en) 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
AR132290A1 (es) 2023-04-05 2025-06-11 Genmab As Composiciones farmacéuticas que comprenden anticuerpos que se unen a cd30 y cd3
TW202504915A (zh) 2023-04-13 2025-02-01 丹麥商珍美寶股份有限公司 以抗ｃｄ３及ｃｄ２０之雙特異性抗體治療淋巴瘤之方法
WO2025057225A1 (en) * 2023-09-14 2025-03-20 Invitrogen Bioservices India Private Limited Engineered antibodies and uses thereof
EP4590715A1 (en) 2023-09-21 2025-07-30 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2025061993A1 (en) 2023-09-21 2025-03-27 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2025116732A1 (en) * 2023-12-01 2025-06-05 Rijksuniversiteit Groningen Methods and kits for detecting proliferating cells
WO2025199352A2 (en) 2024-03-20 2025-09-25 Juno Therapeutics, Inc. Antibodies specific for solute carrier family 34 member 2 (slc34a2)
WO2025240670A2 (en) 2024-05-15 2025-11-20 Abalytics Oncology, Inc. Anti-pd-1 antibodies and related binding molecules and methods and uses thereof

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
AU751659B2 (en) 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
PT1150918E (pt) 1999-02-03 2005-01-31 Biosante Pharmaceuticals Inc Metodo de fabrico de particulas terapeuticas de fosfato de calcio
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
SI1523496T1 (sl) 2002-07-18 2011-11-30 Merus B V Rekombinantno proizvajanje zmesi protiteles
ES2744275T3 (es) 2002-10-17 2020-02-24 Genmab As Anticuerpos monoclonales humanos contra CD20 para su uso en el tratamiento de esclerosis múltiple
PL1737891T3 (pl) 2004-04-13 2013-08-30 Hoffmann La Roche Przeciwciała przeciw selektynie p
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
JP2008528668A (ja) * 2005-02-03 2008-07-31 アンチトープ リミテッド ヒト抗体及びタンパク質
CA2596925C (en) 2005-02-08 2017-07-04 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Method for improving expression level and stability of antibody
DK3050963T3 (da) 2005-03-31 2019-12-09 Chugai Pharmaceutical Co Ltd Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement
WO2010080538A1 (en) 2008-12-19 2010-07-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500352A1 (en) 2005-08-19 2012-09-19 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007042261A2 (en) 2005-10-11 2007-04-19 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
KR101516823B1 (ko) 2006-03-17 2015-05-07 바이오겐 아이덱 엠에이 인코포레이티드 안정화된 폴리펩티드 조성물
EP1999154B1 (en) 2006-03-24 2012-10-24 Merck Patent GmbH Engineered heterodimeric protein domains
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
CN103694350B (zh) 2007-04-03 2018-04-24 安进研发（慕尼黑）股份有限公司 跨物种特异性CD3-ε结合结构域
US20100183615A1 (en) * 2007-04-03 2010-07-22 Micromet Ag Cross-species-specific bispecific binders
EP3424951A1 (en) 2007-06-21 2019-01-09 MacroGenics, Inc. Covalent diabodies and uses thereof
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
DE102008039957A1 (de) 2008-08-27 2010-03-04 Continental Automotive Gmbh Verfahren zur Ermittlung eines Unfallschwerekriteriums mittels eines Beschleunigungssignals und eines Körperschallsignals
JP5397668B2 (ja) 2008-09-02 2014-01-22 ソニー株式会社 記憶素子および記憶装置
FR2935974B1 (fr) 2008-09-15 2010-10-08 Centre Nat Rech Scient Derives de metalloporphyrines, nanoparticules les comprenant
US10981998B2 (en) * 2008-10-01 2021-04-20 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
JP2012505654A (ja) * 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
ES2609043T3 (es) 2009-11-30 2017-04-18 Janssen Biotech, Inc. Anticuerpos mutantes Fc con funciones de efecto abladas
US8786135B2 (en) 2010-03-25 2014-07-22 Mitsubishi Electric Research Laboratories, Inc. Wireless energy transfer with anisotropic metamaterials
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
TWI653333B (zh) * 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
PL2560993T3 (pl) 2010-04-20 2024-11-04 Genmab A/S Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
NZ604003A (en) 2010-05-27 2015-04-24 Genmab As Monoclonal antibodies against her2
ES2573135T3 (es) * 2010-07-14 2016-06-06 Merck Sharp & Dohme Corp. Anticuerpo monoclonal anti-ADDL y usos del mismo
AR082693A1 (es) * 2010-08-17 2012-12-26 Roche Glycart Ag Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf
EP2609111B1 (en) 2010-08-24 2017-11-01 F. Hoffmann-La Roche AG Bispecific antibodies comprising a disulfide stabilized-fv fragment
CN103068847B (zh) 2010-08-24 2019-05-07 罗切格利卡特公司 可活化的双特异性抗体
RS59589B1 (sr) 2010-11-05 2019-12-31 Zymeworks Inc Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
MX349057B (es) * 2010-11-30 2017-07-07 Chugai Pharmaceutical Co Ltd Agente terapeutico que induce citotoxicidad.
WO2012113813A1 (en) 2011-02-23 2012-08-30 F. Hoffmann-La Roche Ag Antibodies against human il33r and uses thereof
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
EA033677B1 (ru) 2011-05-21 2019-11-15 Macrogenics Inc Cd3-связывающие молекулы, способные к связыванию с cd3 человека и cd3, не являющимся человеческим
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
SG10201805291TA (en) 2011-10-27 2018-08-30 Genmab As Production of heterodimeric proteins
KR102086061B1 (ko) * 2012-01-27 2020-03-11 프로테나 바이오사이언시즈 리미티드 알파-시누클레인을 인식하는 인간화된 항체
WO2014006217A1 (en) * 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
MX373245B (es) 2013-07-05 2020-05-11 Genmab As Anticuerpos cd3 humanizados o quiméricos.
AU2014287011A1 (en) * 2013-07-12 2016-02-25 Zymeworks Inc. Bispecific CD3 and CD19 antigen binding constructs
EP3736292B1 (en) * 2013-12-17 2024-05-08 Genentech, Inc. Anti-cd3 antibodies and methods of use
CN114478792A (zh) 2015-01-08 2022-05-13 根马布股份公司 针对cd3和cd20的双特异性抗体
UA128057C2 (uk) 2015-07-15 2024-03-27 Ґенмаб А/С Гуманізоване або химерне антитіло, яке зв'язує cd3 людини
CH713600A2 (de) 2017-03-21 2018-09-28 Digi Sens Ag Vorrichtung und Verfahren zum Messen einer Last.
WO2019034580A1 (en) * 2017-08-14 2019-02-21 Morphosys Ag HUMANIZED ANTIBODIES FOR CD3
US20230355753A1 (en) * 2020-09-10 2023-11-09 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
MX2023002545A (es) * 2020-09-10 2023-03-14 Genmab As Anticuerpo biespecifico contra cumulo de diferenciacion 3 (cd3) y cumulo de diferenciacion 20 (cd20) en terapia de combinacion para el tratamiento de linfoma difuso de celulas b grandes.
CA3189883A1 (en) * 2020-09-10 2022-03-17 Brian Elliott Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
BR112023004327A2 (pt) * 2020-09-10 2023-04-04 Genmab As Método para tratar leucemia linfocítica crônica em um sujeito humano

Also Published As

Publication number Publication date
KR20160027177A (ko) 2016-03-09
CN106255507A (zh) 2016-12-21
IL276530A (en) 2020-09-30
IL311371B2 (en) 2024-09-01
US20160168247A1 (en) 2016-06-16
JP6546162B2 (ja) 2019-07-17
SI4249515T1 (sl) 2025-11-28
PT3016681T (pt) 2020-03-26
SMT202000287T1 (it) 2020-07-08
EP4631978A2 (en) 2025-10-15
ME03675B (me) 2020-10-20
RS60131B1 (sr) 2020-05-29
AU2020202792B2 (en) 2022-06-23
KR20230073341A (ko) 2023-05-25
US20230374131A1 (en) 2023-11-23
EP3016681B1 (en) 2019-12-18
KR102531517B1 (ko) 2023-05-12
JP6619342B2 (ja) 2019-12-11
WO2015104346A1 (en) 2015-07-16
HUE048722T2 (hu) 2020-08-28
IL276530B (en) 2022-03-01
EP4631978A3 (en) 2025-12-24
CN120365424A (zh) 2025-07-25
WO2015001085A1 (en) 2015-01-08
EP3693385A1 (en) 2020-08-12
HUE072527T2 (hu) 2025-11-28
BR122023002590B1 (pt) 2023-12-05
AU2022203851B2 (en) 2025-07-24
JP7208129B2 (ja) 2023-01-18
DK3016681T3 (da) 2020-03-09
MX2020004503A (es) 2020-08-13
JP7389833B2 (ja) 2023-11-30
MX2015017487A (es) 2016-03-21
PT4249515T (pt) 2025-09-08
JP2024026114A (ja) 2024-02-28
AU2014286116A1 (en) 2016-02-04
UA119646C2 (uk) 2019-07-25
LT4249515T (lt) 2025-08-25
IL243127B (en) 2020-08-31
CA2915575A1 (en) 2015-01-08
JP7757247B2 (ja) 2025-10-21
EP3091998B1 (en) 2025-08-20
CN113248615A (zh) 2021-08-13
DK4249515T3 (en) 2025-09-15
PL3016681T3 (pl) 2020-06-15
JP2017505121A (ja) 2017-02-16
AU2020202792B9 (en) 2022-07-07
KR102363220B1 (ko) 2022-02-15
SG11201510739TA (en) 2016-01-28
US20160333095A1 (en) 2016-11-17
US20200123255A1 (en) 2020-04-23
US10407501B2 (en) 2019-09-10
ES2776706T3 (es) 2020-07-31
ES3038421T3 (en) 2025-10-13
IL290613B2 (en) 2024-11-01
EP4249515A2 (en) 2023-09-27
JP2022101539A (ja) 2022-07-06
SI3016681T1 (sl) 2020-04-30
KR20220025210A (ko) 2022-03-03
JP7104000B2 (ja) 2022-07-20
CN106255507B (zh) 2025-05-02
JP2020048564A (ja) 2020-04-02
JP2022163009A (ja) 2022-10-25
EP3091998A1 (en) 2016-11-16
IL311371B1 (en) 2024-05-01
JP2020005635A (ja) 2020-01-16
RS67220B1 (sr) 2025-10-31
AU2025256200A1 (en) 2025-11-13
KR102813816B1 (ko) 2025-05-29
EA201690167A1 (ru) 2016-06-30
US10465006B2 (en) 2019-11-05
IL311371A (en) 2024-04-01
MX373245B (es) 2020-05-11
NZ715896A (en) 2022-02-25
KR20250078622A (ko) 2025-06-02
EP4249515A3 (en) 2023-11-15
AU2020202792A1 (en) 2020-05-21
SMT202500322T1 (it) 2025-11-10
LT3016681T (lt) 2020-03-25
EP3016681A1 (en) 2016-05-11
JP2016529882A (ja) 2016-09-29
HRP20251127T1 (hr) 2025-11-21
IL290613A (en) 2022-04-01
IL290613B1 (en) 2024-07-01
EP4249515B1 (en) 2025-06-18
FI4249515T3 (fi) 2025-09-02
CN118063621A (zh) 2024-05-24
DK3016681T5 (da) 2020-05-04
HRP20200382T1 (hr) 2020-06-12
CN113248615B (zh) 2025-07-04
US20200199229A1 (en) 2020-06-25
CY1122840T1 (el) 2021-05-05
BR112015032986A2 (pt) 2017-08-22
AU2022203851A1 (en) 2022-06-23
CN105722529A (zh) 2016-06-29
US11613575B2 (en) 2023-03-28
CN105722529B (zh) 2021-06-08
FIC20250036I1 (fi) 2025-12-09
ZA201800385B (en) 2019-09-25
HK1231369A1 (zh) 2017-12-22
NL301352I2 (nl) 2025-12-16

Similar Documents

Publication Publication Date Title
IL311371A (en) CD3 antibodies of human origin or chimeras
SG11201509609SA (en) Chimeric antigen receptor-targeting monoclonal antibodies
ZA201504697B (en) Antibodies comprising chimeric constant domains
EP2931314A4 (en) CHIMERIC AND HUMANIZED ANTI-HISTON ANTIBODIES
IL244784A0 (en) chimeric antigen receptor
ZA201506568B (en) Anti-tnf-anti-il-17 bispecific antibodies
EP3083698A4 (en) Monoclonal anti-tk1 antibodies
SI3549599T1 (sl) Protitelesa proti csf-1r
EP2970445A4 (en) Humanized anti-n2 antibodies
HK40111469A (zh) 人源化或嵌合cd3抗体
HK1255635A1 (zh) 人源化或嵌合的cd3抗体